Fascin-1 and its role as a serological marker in prostate cancer: a prospective case

Fascin-1 and its role as a serological marker in prostate cancer: a prospective case–control study

Published:2021-10 Issue:9 Volume:7 Page:
ISSN:2056-5623
Container-title:Future Science OA
language:en
Short-container-title:Future Science OA

Author:

Tătaru Octavian Sabin¹^ORCID,Martha Orsolya²,Crocetto Felice³^ORCID,Barone Biagio³^ORCID,Voidazan Septimiu⁴,Borda Angela⁵,Sin Anca⁶,Hutanu Adina⁷^ORCID,Loghin Andrada⁵,Sin Ileana⁶,Porav-Hodade Daniel²,Chibelean Calin Bogdan²,Vartolomei Liliana¹,Lucarelli Giuseppe⁸^ORCID,Ferro Matteo⁹^ORCID,Osan Virgil Gheorghe¹,Buonerba Carlo¹⁰^ORCID,Vartolomei Mihai Dorin⁶^ORCID

Affiliation:

1. I.O.S.U.D., George Emil Palade University of Medicine & Pharmacy, Science & Technology, Targu Mures, Romania

2. Department of Urology, George Emil Palade University of Medicine & Pharmacy, Science & Technology, Targu Mures, Romania

3. Department of Neurosciences, Reproductive Sciences & Odontostomatology, University of Naples Federico II, Naples, Italy

4. Department of Epidemiology, George Emil Palade University of Medicine & Pharmacy, Science & Technology, Targu Mures, Romania

5. Department of Histology, George Emil Palade University of Medicine & Pharmacy, Science & Technology, Targu Mures, Romania

6. Department of Cell & Molecular Biology, George Emil Palade University of Medicine & Pharmacy, Science & Technology, Targu Mures, Romania

7. C.C.M.A.F., George Emil Palade University of Medicine & Pharmacy, Science & Technology, Targu Mures, Romania

8. Department of Emergency & Organ Transplantation-Urology, Andrology & Kidney Transplantation Unit, University of Bari, Bari, Italy

9. Division of Urology, European Institute of Oncology (IEO)-IRCCS, Milan, Italy

10. Department of Oncology & Hematology, Regional Reference Center for Rare Tumors, AOU Federico II of Naples, Naples, Italy

Abstract

Aim: This study aims to investigate any modification of serological FSCN1 in prostate cancer patients compared with patients without neoplasia. Material & methods: Clinical data and blood specimens from patients with and without prostate cancer were obtained. A quantitative sandwich ELISA method was used to determine serological values of FSCN1. Results: Although serum values of FSCN1 were dissimilar in the two cohorts of patients (6.90 vs 7.33 ng/ml), the difference was not statistically significant (p = 0.20). Serum values of FSCN1 stratified for Gleason score groups were not significantly distinguishable (p = 0.65). A negative correlation (rho = -0.331; p = 0.009) was reported between FSCN1 and age. Conclusion: Further studies are required to evaluate a possible diagnostic role of FSCN1 in prostate cancer.

Publisher

Future Science Ltd

Subject

Biotechnology

Link

https://www.future-science.com/doi/pdf/10.2144/fsoa-2021-0051

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The FSCN1 gene rs2966447 variant is associated with increased serum fascin-1 levels and breast cancer susceptibility;Gene;2024-11

2. A Highly Accurate Model for Screening Prostate Cancer Using Propensity Index Panel of Ten Genes;Journal of Computational Biology;2023-12-01

3. ΔPSap4#5 surface-functionalized abiraterone-loaded nanoparticle successfully inhibits carcinogen-induced prostate cancer in mice: a mechanistic investigation;Cancer Nanotechnology;2023-09-04

4. Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2023-08-26

5. Targeting FSCN1 with an oral small-molecule inhibitor for treating ocular neovascularization;Journal of Translational Medicine;2023-08-18